Galecto Gains Momentum with New Drug Class and Strong Funding
Guggenheim initiates coverage on Galecto with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029.
/ 1665 items
#XY↓
FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.
Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.
IDEAYA Gets FDA Green Light for Groundbreaking Cancer Treatment
IDEAYA Biosciences receives FDA clearance for IDE034, a first-in-class dual-target cancer therapy aimed at lung, colorectal, and head and neck tumors.
First Stargardt Disease Treatment Shows 36% Lesion Reduction
Belite Bio's tinlarebant demonstrates first successful Phase 3 results for Stargardt disease, reducing retinal lesion growth by 36% in adolescent patients.
INVO Fertility Expands Midwest Presence with Family Beginnings Acquisition
INVO Fertility announces planned acquisition of Indiana's Family Beginnings clinic, marking its second acquisition and expanding its nationwide fertility care network across the Midwest.